Show simple item record

dc.contributor.authorWhitehead, Michaelen
dc.contributor.authorOsborne, Andrewen
dc.contributor.authorWiddowson, Peter Sen
dc.contributor.authorYu Wai Man, Patricken
dc.contributor.authorMartin, Keithen
dc.date.accessioned2019-07-29T23:30:21Z
dc.date.available2019-07-29T23:30:21Z
dc.date.issued2019-01en
dc.identifier.issn2314-6745
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/295039
dc.description.abstractDiabetic retinopathy (DR) is the commonest cause of blindness in the working-age population of the developed world. The molecular pathophysiology of DR is complex and a complete spatiotemporal model of the disease is still being elucidated. Recently, a role for angiopoietin (Ang) proteins in the pathophysiology of DR has been proposed by several research groups, and several aspects of Ang signalling are being explored as novel therapeutic strategies. Here we review the role of the Ang proteins in two important forms of DR, diabetic macular oedema and proliferative diabetic retinopathy. The function of the Ang proteins in regulating blood vessel permeability and neovascularisation is discussed and we also evaluate recent preclinical and clinical studies highlighting the potential benefits of modulating Ang signalling as a treatment for DR.
dc.description.sponsorshipMW and PYWM are funded by Medical Research Council (UK) grants. MW, PYWM and AO 386 receive support from The Novo Nordisk UK Research Foundation, the Cambridge Eye Trust and 387 the Jukes Glaucoma Research Fund. AO, PYWM and KRM also hold Fight for Sight (UK) awards. 388 PYWM is also supported by a Clinician Scientist Fellowship Award (G1002570), the Isaac Newton 389 Trust, the UK National Institute of Health Research (NIHR) as part of the Rare Diseases 390 Translational Research Collaboration, and the NIHR Biomedical Research Centre based at 391 Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. Research in 392 the laboratory is supported by core funding from Wellcome and MRC to the Wellcome-MRC 393 Cambridge Stem Cell Institute.
dc.format.mediumElectronic-eCollectionen
dc.languageengen
dc.publisherHindawi Publishing Corporation
dc.rightsAll rights reserved
dc.subjectAnimalsen
dc.subjectHumansen
dc.subjectDiabetic Retinopathyen
dc.subjectDiabetes Mellitusen
dc.subjectDiabetes Complicationsen
dc.subjectAngiopoietinsen
dc.subjectHypoglycemic Agentsen
dc.subjectSignal Transductionen
dc.subjectMacular Edemaen
dc.titleAngiopoietins in Diabetic Retinopathy: Current Understanding and Therapeutic Potential.en
dc.typeArticle
prism.publicationDate2019en
prism.publicationNameJournal of diabetes researchen
prism.startingPage5140521
prism.volume2019en
dc.identifier.doi10.17863/CAM.42116
dcterms.dateAccepted2019-07-19en
rioxxterms.versionofrecord10.1155/2019/5140521en
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2019-01en
dc.contributor.orcidWhitehead, Michael [0000-0002-5494-8302]
dc.contributor.orcidYu-Wai-Man, Patrick [0000-0001-7847-9320]
dc.contributor.orcidMartin, Keith [0000-0002-9347-3661]
dc.identifier.eissn2314-6753
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idMRC (1944187)
pubs.funder-project-idCambridge Eye Trust (unknown)
cam.orpheus.successMon Jun 08 08:20:39 BST 2020 - The item has an open VoR version.*
rioxxterms.freetoread.startdate2022-07-29


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record